德国真实世界研究:氨基酮戊酸人工日光光动力治疗日光性角化病的可行性与效果
本研究为前瞻性、非干预性、多中心研究(ArtLight,NCT05725213),纳入德国面部和头皮Olsen 1或2级日光性角化病(AK)患者224例,接受氨基酮戊酸(MAL)人工日光光动力治疗(ADL-PDT)。治疗3个月后焦点区域病灶数减少71%(P<0.001),93.3%患者疼痛为无或轻度(NRS 0-3),AKASI中位数从6.2降至3.4(95%CI 2.4-3.0;P<0.001),未报告新的安全性信号。结论认为MAL-ADL-PDT在真实世界条件下具有临床可行性。
要点
- MAL-ADL-PDT治疗3个月后焦点区域病灶数减少71%。
- 93.3%患者治疗期间无痛或轻度疼痛(NRS 0-3)。
- AKASI中位数从基线6.2降至3个月3.4,研究者与患者满意度高。
核心结论
- MAL-ADL-PDT在真实世界条件下治疗面部和头皮AK具有临床可行性,表现为有效减少病灶且疼痛轻微。
研究设计与样本
- 前瞻性、非干预性、多中心研究(ArtLight,NCT05725213),纳入德国面部和头皮Olsen 1或2级AK患者224例,接受MAL-ADL-PDT(160 mg g-1 MAL霜)。
主要发现
- 治疗3个月后焦点区域(10×10-cm区域)病灶数减少71%(P<0.001)。
- 93.3%患者治疗期间无痛或轻度疼痛(NRS评分0-3)。
- AKASI中位数从基线6.2降至3个月3.4(95%CI 2.4-3.0;P<0.001)。
- 82.8%研究者和80.0%患者对治疗满意,未报告新的安全性信号。
临床怎么用
- MAL-ADL-PDT可作为面部和头皮AK患者一种便利的、全年可用的、近乎无痛的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Artificial daylight photodynamic therapy (ADL-PDT) is an alternative, all-year applicable, nearly painless treatment approach for actinic keratosis (AK) with comparable effectiveness to daylight or conventional PDT. At the time this study was initiated, methyl aminolaevulinate (MAL) was the only photosensitizer approved for ADL-PDT in Germany. OBJECTIVES: To gain comprehensive insights into the practicability of MAL-ADL-PDT in patients with AK using different artificial daylight sources under real-world conditions. METHODS: This prospective, noninterventional, multicentre study (ArtLight, NCT05725213) enrolled patients with Olsen grade 1 or 2 AK on the face and scalp in Germany. Patients were treated with MAL-ADL-PDT (160 mg g-1 MAL cream). The primary outcome measure was the practicability of MAL-ADL-PDT assessed as rate of resolved AK lesions in the focus area (10 × 10-cm area within the treatment area). Secondary outcomes included treatment-associated pain (numeric rating scale, NRS), Actinic Keratosis Area and Severity Index (AKASI), total lesion count over time, skin preparation, safety, overall assessment of effectiveness, tolerability, adherence and patient satisfaction. RESULTS: In total, 224 patients [median age 75.0 (range 50-91) years, 85.3% male, 62.5% AK Olsen grade 2, 55.4% treatment-naïve] were included and treated with MAL-ADL-PDT. Three months after treatment, lesion counts were reduced in the focus area by 71% (P < 0.001) indicating practicability of the treatment. Nearly all patients (93.3%) experienced no or mild pain during PDT (NRS score 0-3). Median AKASI decreased from 6.2 at baseline to 3.4 at month 3 (95% confidence interval 2.4-3.0; P < 0.001). The majority of investigators (82.8%) and patients (80.0%) were satisfied with the treatment. No new safety signals were reported. CONCLUSIONS: The clinical practicability of MAL-ADL-PDT was demonstrated under real-world conditions by effective lesion reduction and predominantly none-to-mild procedural pain. Thus, MAL-ADL-PDT is a convenient way for healthcare professionals to deliver PDT treatment to patients with AK located on the face and scalp. Actinic keratosis is a skin condition that can lead to skin cancer, and is caused by sun damage. About 200,000 people in Germany are newly diagnosed each year. Artificial daylight photodynamic therapy (ADL-PDT) is a nearly painless treatment for actinic keratosis. This method can be used year-round. This study looked at ADL-PDT with methyl aminolaevulinate (MAL) applied to the skin. We aimed to determine how practical ADL-PDT with MAL is for patients with actinic keratosis when using different ADL lamps. The study involved 224 patients with mild-to-moderate actinic keratosis on their face and scalp. Before applying ADL-PDT, we treated the affected skin with a cream containing MAL, followed by illumination of the affected skin locations. We assessed the rate of resolved lesions and the level of pain patients felt during the treatment. Three months after treatment, the number of lesions overall had decreased by 71%. Most patients (93.3%) reported mild to no pain during the procedure. The severity of the condition also improved significantly, and patients and doctors expressed high satisfaction with the treatment. The treatment was well tolerated. Our study findings suggest that MAL-ADL-PDT could be a practical therapy for people with actinic keratosis, as there were reported benefits from the nearly painless procedure for effective lesion reduction.
引用
- Philipp-Dormston WG, Brückner M, Hoffmann M, et al. Artificial daylight photodynamic therapy using methyl aminolaevulinate in a real-world setting in Germany: results from the noninterventional study ArtLight. Br J Dermatol. 2025. PMID: 39509708. doi:10.1093/bjd/ljae437
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。